On September 3, 2019 SCL Health reported continues to build on its commitment to person-centered care and transforming the patient experience through innovative and cutting-edge cancer care (Press release, Strata Oncology, SEP 3, 2019, View Source [SID1234539220]). Strata Oncology, Inc. is a precision medicine company dedicated to transforming cancer care by building a platform to systematize precision oncology across a network of health systems. By partnering with the Strata Precision Oncology Network (the Network), SCL Health will be able to provide the benefits of the latest technology and clinical research in precision oncology to patients across Colorado and Montana.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Through the Network, SCL Health patients will benefit from Strata’s precision oncology platform and comprehensive treatment program for personalized cancer care. Eligible cancer patients will have access to routine tumor molecular profiling, rapid interpretation of test results and the ability to participate in local precision therapy clinical trials.

"As our understanding of cancer becomes more complex, the advent of targeted therapies and immune-based therapies allow us to look at the genes that drive cancer. This has led to a whole new class of medications that enable us to treat cancer in a more precise way with potentially fewer side effects," said Alan Miller, MD, Chief Medical Director of Oncology and Associate Chief Medical Director of Clinical Research for SCL Health. "In order to leverage these new treatments, we need to characterize the cancer right down to its genetic roots. As part of the Network, we are able to offer this characterization at no cost to the patient and the results will ultimately inform a more precise treatment plan."

SCL Health is dedicated to empowering cancer patients through providing access to proven therapies and the latest scientifically-proven outcomes. SCL Health is one of two health systems in Colorado and the only health system in Montana to be part of the Strata Precision Oncology Network. This partnership will transform how patients find and access cutting-edge, quality cancer care in the Colorado-Montana region.

Media Contact:
Britta Robinson
Communications Director
303-813-5242
[email protected]

On September 3, 2019 CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, reported that Geert Kersten, Chief Executive Officer, is scheduled to present at the H.C. Wainwright 21st Annual Global Investor Conference on Tuesday, September 10th at 11:15 a.m. Eastern Time (Press release, Cel-Sci, SEP 3, 2019, View Source [SID1234539236]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of Mr. Kersten’s presentation will be available in the Investors section of the Company’s website at View Source The webcast will be available for 90 days following the presentation.

On August 27, 2019 Vaccitech, a clinical-stage T cell immunotherapy company developing products to treat and prevent cancer and infectious diseases (ID), reported that it has appointed Bill Enright as its new Chief Executive Officer (CEO) (Press release, Vaccitech, AUG 27, 2019, View Source [SID1234539000]). Mr. Enright succeeds Tom Evans, MD who will make a planned transition to the role of Vaccitech’s Chief Scientific Officer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Bill joins Vaccitech after an accomplished 11 years as CEO at Gaithersburg-based Altimmune Inc, a company developing novel immunotherapies and vaccines. He led Altimmune through a significant period of growth including a Series B financing, the acquisition of Immune Targeting Systems – a UK T-cell vaccine company – and taking the company public on NASDAQ through the acquisition of PharmAthene. Bill’s prior experience includes executive and management roles at GenVec (now Intrexon), Biotech Venture Management and Life Technologies Corporation (now ThermoFisher).

Dr. Andrew Mclean, Vaccitech Board Member, Oxford Science Innovation, said, "we’re incredibly excited to welcome Bill Enright to lead Vaccitech to build a world-leading T-cell induction immunotherapy company."

"I am delighted to join Vaccitech during this exciting growth phase, ahead of pivotal Phase II data from its lead influenza program and several other key pipeline inflection points. I have been very impressed by the Company’s management team as well as its innovative T cell induction platform. I am looking forward to working with the team to drive the company through the next phase of its development." said Bill Enright.

Having successfully built Vaccitech to a late clinical stage biopharmaceutical company, in his new role as CSO, Tom Evans MD, will focus more specifically on the science, research and development that underpin Vaccitech’s next generation T-cell induction products.

"We believe that Bill’s background and leadership skills are well suited to the Company’s next phase of development and are looking forward to welcoming him to the role. We are extremely grateful to Tom Evans under whose leadership the company has grown rapidly, with over 2000 participants currently in clinical trials. We look forward to Tom’s continuing involvement and excellent scientific leadership as Vaccitech’s CSO.’ added Robin Wright, Vaccitech Chairman.

On September 3, 2019 ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, reported its participation in the 21st Annual Global Investment Conference sponsored by H.C. Wainwright & Co. LLC (Press release, ProMIS Neurosciences, SEP 3, 2019, View Source [SID1234539185]). The conference is being held September 8-10, 2019 at the New York Palace Hotel in New York.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ProMIS’ Executive Chairman, Eugene Williams will provide overviews of its novel drug discovery and development programs for Alzheimer’s disease, Parkinson’s disease and ALS (amyotrophic lateral sclerosis) Tuesday, September 10th at 10:25 am ET. The audio webcast and slides of Mr. Williams’ presentation will be archived and available on ProMIS’ web site and through the following link View Source

On September 3, 2019 argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, reported that Tim Van Hauwermeiren, Chief Executive Officer, will present at the Morgan Stanley 17th Annual Global Healthcare Conference on Monday, September 9, 2019 at 10:30 am ET in New York (Press release, argenx, SEP 3, 2019, View Source [SID1234539204]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live webcast may be accessed on the homepage of the argenx website at www.argenx.com. Shortly after the presentation, a replay of the webcast will be available for 90 days on the argenx website.